Onkológia 4/2021
Treatment of mucomycosis in immunocompromised patients
Mucomycosis is a rare disease with high morbidity and mortality especially in immunocompromised patients. Diagnostics and therapy are difficult and often delayed with fatal consequences due to rapidly progressive disease. Immediate interdisciplinary cooperation with urgent intervention is lifesaving with higher probability of better prognosis. High-dose liposomal amphotericin B is strongly recommended in first line treatment, while intravenous and delayed release tablet posakonazole or intravenous isavuconazole are recommended with moderate strength. Both azoles are strongly recommended also in salvage treatment.
Keywords: mucormycosis, immunocompromised patient, therapy, diagnostics, guidelines
